Amb motiu del tancament d'estiu, la validació de documents es reprendrà a partir del 28 d'agost de 2026. Disculpeu les molèsties.
Con motivo del cierre de verano, la validación de documentos se reanudará a partir del 28 de agosto de 2026. Disculpad las molestias
Due to the summer closure, document validation will resume starting August 28, 2026. We apologize for any inconvenience.

Files

2024_NatCom_Urease_SanchezS.pdf (3.44 MB)

Document type

Article

Version

Published version

Publication date

2024-11-15

Publication license

cc-by-nc-nd (c) Choi, Hyunsik et al., 2024
Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/220757

Urease-powered nanomotor containing STING agonist for bladder cancer immunotherapy

Journal Title

Authors

Director/Tutor

Journal ISSN

Volume Title

Related resource

https://doi.org/10.1038/s41467-024-54293-z

Abstract

Most non-muscle invasive bladder cancers have been treated by transurethral resection and following intravesical injection of immunotherapeutic agents. However, the delivery efficiency of therapeutic agents into bladder wall is low due to frequent urination, which leads to the failure of treatment with side effects. Here, we report a urease-powered nanomotor containing the agonist of stimulator of interferon genes (STING) for the efficient activation of immune cells in the bladder wall. After characterization, we perform in vitro motion analysis and assess in vivo swarming behaviors of nanomotors. The intravesical instillation results in the effective penetration and retention of nanomotors in the bladder. In addition, we confirm the anti-tumor effect of nanomotor containing the STING agonist (94.2% of inhibition), with recruitment of CD8+ T cells (11.2-fold compared with PBS) and enhanced anti-tumor immune responses in bladder cancer model in female mice. Furthermore, we demonstrate the better anti-tumor effect of nanomotor containing the STING agonist than those of the gold standard Bacille Calmette-Guerin therapy and the anti-PD-1 inhibitor pembrolizumab in bladder cancer model. Taken together, the urease-powered nanomotor would provide a paradigm as a next-generation platform for bladder cancer immunotherapy. Self-propelling micro/nanomotors represent a therapeutic option for drug delivery. Here the authors report the design and characterization of a biodegradable urease-powered nanomotor containing STING agonist, promoting anti-tumor immune responses in bladder cancer models.

Subject

Immunoteràpia, Càncer de bufeta

Subject (English)

Immunotheraphy, Bladder cancer

Citation

Collections

Articles publicats en revistes (Institut de Bioenginyeria de Catalunya (IBEC))

Citation

CHOI, Hyunsik, et al. Urease-powered nanomotor containing STING agonist for bladder cancer immunotherapy. Nature Communications. 2024. Vol. 15. ISSN 2041-1723. [consulted: 15 of August of 2026]. Available at: https://hdl.handle.net/2445/220757

Export metadata

JSON - METS

Share record